PL359624A1 - Clear aqueous anaesthetic composition - Google Patents

Clear aqueous anaesthetic composition

Info

Publication number
PL359624A1
PL359624A1 PL00359624A PL35962400A PL359624A1 PL 359624 A1 PL359624 A1 PL 359624A1 PL 00359624 A PL00359624 A PL 00359624A PL 35962400 A PL35962400 A PL 35962400A PL 359624 A1 PL359624 A1 PL 359624A1
Authority
PL
Poland
Prior art keywords
clear aqueous
propofol
compositions
composition
hydroxypropyl
Prior art date
Application number
PL00359624A
Other languages
English (en)
Polish (pl)
Inventor
Srikanth Pai
Sangeeta Rivankar
Shilpa Kocharekar
Original Assignee
Bharat Serums & Vaccines Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd. filed Critical Bharat Serums & Vaccines Ltd.
Publication of PL359624A1 publication Critical patent/PL359624A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00359624A 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition PL359624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (h) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (1)

Publication Number Publication Date
PL359624A1 true PL359624A1 (en) 2004-08-23

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00359624A PL359624A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Country Status (26)

Country Link
US (1) US7138387B2 (h)
EP (1) EP1299095B1 (h)
JP (1) JP4907833B2 (h)
KR (1) KR100810066B1 (h)
CN (1) CN1254237C (h)
AP (1) AP2002002674A0 (h)
AT (1) ATE267592T1 (h)
AU (2) AU2001235972B2 (h)
BG (1) BG107463A (h)
BR (1) BR0017268A (h)
CA (1) CA2414064C (h)
DE (1) DE60011149T2 (h)
DK (1) DK1299095T3 (h)
EA (1) EA005589B1 (h)
ES (1) ES2222271T3 (h)
HU (1) HUP0301646A3 (h)
IL (1) IL153387A0 (h)
IN (1) IN187686B (h)
MX (1) MXPA02012611A (h)
NO (1) NO20025999L (h)
NZ (1) NZ523643A (h)
PL (1) PL359624A1 (h)
PT (1) PT1299095E (h)
WO (1) WO2001097796A1 (h)
YU (1) YU2703A (h)
ZA (1) ZA200300336B (h)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (h) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2005517679A (ja) * 2001-12-28 2005-06-16 ギルフォード ファーマシューティカルズ インコーポレイテッド プロポフォールの水溶性プロドラッグの水ベースの薬学的製剤
DE60305438T2 (de) * 2002-02-01 2006-12-21 Shimoda Biotech (Pty.) Ltd., Mill Park Lyophilisierte pharmazeutische zusammensetzung von propofol
NZ538255A (en) 2002-07-29 2006-11-30 Transform Pharmaceuticals Inc Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
EP1704858A4 (en) * 2004-01-14 2008-06-04 Otsuka Pharma Co Ltd PROPOFOL-CONTAINING FAT-EMULSION PREPARATION
CA2580202A1 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
JP2009504634A (ja) * 2005-08-12 2009-02-05 ブハラット セルムズ アンド ヴァクシンズ リミテッド プロポフォールを含む水性麻酔剤組成物
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
EP2269116A4 (en) * 2008-03-11 2011-09-07 3M Innovative Properties Co PHOTOGRAPHIC MASKS HAVING PROTECTIVE LAYER
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US9096712B2 (en) 2009-07-21 2015-08-04 3M Innovative Properties Company Curable compositions, method of coating a phototool, and coated phototool
CN102549042B (zh) 2009-09-16 2015-01-28 3M创新有限公司 氟化涂料和用其制作的底片
CN102686642B (zh) 2009-09-16 2016-06-29 3M创新有限公司 氟化涂料和用其制作的底片
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
EP2484350B1 (de) * 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
DK2785352T3 (da) 2011-11-29 2020-05-25 Jurox Pty Ltd Stabile injicerbare farmaceutiske sammensætninger omfattende 2-hydroxypropyl-beta-cyclodextrin og alfaxalon
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
US10646439B2 (en) * 2016-01-29 2020-05-12 Cuda Anesthetics, Llc Aqueous pharmaceutical formulation comprising propofol
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
ATE267592T1 (de) 2004-06-15
CN1454085A (zh) 2003-11-05
MXPA02012611A (es) 2004-07-30
EA200300047A1 (ru) 2003-06-26
HUP0301646A3 (en) 2005-06-28
CN1254237C (zh) 2006-05-03
AP2002002674A0 (en) 2002-12-31
NO20025999D0 (no) 2002-12-13
PT1299095E (pt) 2004-10-29
EP1299095A1 (en) 2003-04-09
WO2001097796A1 (en) 2001-12-27
DK1299095T3 (da) 2004-10-11
NO20025999L (no) 2002-12-13
JP4907833B2 (ja) 2012-04-04
AU2001235972B2 (en) 2005-07-21
HUP0301646A2 (hu) 2003-09-29
DE60011149D1 (de) 2004-07-01
IL153387A0 (en) 2003-07-06
CA2414064C (en) 2013-01-08
JP2003535893A (ja) 2003-12-02
IN187686B (h) 2002-06-08
KR100810066B1 (ko) 2008-03-05
KR20030023875A (ko) 2003-03-20
BR0017268A (pt) 2003-05-27
ZA200300336B (en) 2004-04-08
ES2222271T3 (es) 2005-02-01
EP1299095B1 (en) 2004-05-26
US20040014718A1 (en) 2004-01-22
US7138387B2 (en) 2006-11-21
YU2703A (sh) 2006-03-03
DE60011149T2 (de) 2005-07-07
AU3597201A (en) 2002-01-02
BG107463A (en) 2003-11-28
CA2414064A1 (en) 2001-12-27
EA005589B1 (ru) 2005-04-28
NZ523643A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
PL359624A1 (en) Clear aqueous anaesthetic composition
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
SE0001899D0 (sv) New compounds
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
RS20050066A (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2171462T3 (es) Ciclodextranos para la reduccion de la extravasacion causada por compuestos citotoxicos.
SI1819227T1 (sl) Farmacevtska formulacija decitabina
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
AR043110A1 (es) Sal de heparina de bajo peso molecular con trietanolamina util como agente terapeutico-antitrombotico de administracion topica, procedimientos para preparar dichas sales, proceso para la eliminacion de la higroscopicidad de la sal de heparina, composiciones farmaceuticas para uso topico en terapia a
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad
BR0109617A (pt) Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0212915A (pt) Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs
IL147901A0 (en) Phenanthroline-7-one derivatives and their therapeutic uses